TSRI chemists develop new method to achieve chemical reaction in pharmaceutical industry
A factory in the north has agreed to stop using chemicals such as benzyl chloride, which caused breathing difficulties, vomiting and burning eyes in local people after a leak in June 2014.
Under the compromise following a class-action suit, the Sarafei Carmel adhesives plant in the northern town of Atlit will not admit wrongdoing but will pay 360,000 shekels ($95,000) in compensation. The deal was approved by the Haifa District Court.
After the leak, residents sued the factory, whose parent company is Carmel Chemicals, also located in Atlit. The residents were represented by a lawyer from the Union for Environmental Defense.
Under the compromise, the factory will stop using benzyl chloride starting in September. It also pledged to stop using three other hazardous materials including formaldehyde, a carcinogen. From September, these substances will no longer be on the list of toxins the factory has a permit to use.
Most of the compensation money will be deposited in an account that the Union for Environmental Defense can use for environmental work.
The factory also said it would pay the fees of the expert witnesses hired by the residents as well as attorneys’ fees – the total cost amounts to 100,000 shekels.
Under the compromise, an expert representing the residents will be able to examine the factory’s list of permitted toxins and inspect the factory annually for compliance.
Sarafei Carmel is located near the Atlit train station, not far from a residential area. In recent years, Atlit residents have been fighting to have the plant closed entirely, even before the chemical leak. In a class action six years ago, Carmel Chemicals was required to pay 450,000 shekels in compensation.
via.HAARETZ
Looking for chemical products? Let suppliers reach out to you!
2026-07-07
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Faces a Compliance Test
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
Recommend Reading
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
This week, the TDI market in China showed a strong upward trend (12.8-12.12)
-
ECHA Adds Three Hazardous Chemicals to the Candidate List
-
March Ethylene Oxide Prices Soar to a Four-Year High in China
-
Early August Shandong Normal Butanol Market in Decline
-
Raw Material Prices Continue to Rise, Anhydrous Hydrogen Fluoride Market Remains Firm in China (12.8-12.12)